In Australia, patients and government at odds over mesothelioma treatment costs.
Burkitt
Vicki
V
D000008:Abdominal Neoplasms / Q000191:economics / Q000628:therapy; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000191:economics; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000191:economics* / Q000627:therapeutic use; D001194:Asbestos / Q000633:toxicity; D001315:Australia / Q000453:epidemiology; D002170:Canada; D002273:Carcinogens; D002945:Cisplatin / Q000008:administration & dosage / Q000191:economics; D003362:Cost-Benefit Analysis; D004781:Environmental Exposure / Q000009:adverse effects; D005971:Glutamates / Q000008:administration & dosage / Q000191:economics; D006076:Government; D006147:Guanine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000191:economics; D017048:Health Care Costs; D006801:Humans; D015994:Incidence; D008119:Lobbying; D008175:Lung Neoplasms / Q000191:economics / Q000628:therapy; D008654:Mesothelioma / Q000191:economics* / Q000453:epidemiology / Q000209:etiology / Q000628:therapy*; D010344:Patient Advocacy; D000068437:Pemetrexed; D011799:Quinazolines / Q000008:administration & dosage / Q000191:economics; D013876:Thiophenes / Q000008:administration & dosage / Q000191:economics; D013899:Thoracic Neoplasms / Q000191:economics / Q000628:therapy; D006113:United Kingdom
D000964:Antimetabolites, Antineoplastic; D002273:Carcinogens; D005971:Glutamates; D011799:Quinazolines; D013876:Thiophenes; D000068437:Pemetrexed; D001194:Asbestos; D006147:Guanine; C068874:raltitrexed; D002945:Cisplatin